Peptron, Inc.
KOSDAQ 087010.KQ
Peptron, Inc. Free Cash Flow Yield on January 14, 2025: -0.69%
Peptron, Inc. Free Cash Flow Yield is -0.69% on January 14, 2025, a 62.21% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
-
Peptron, Inc. 52-week high Free Cash Flow Yield is -0.46% on November 15, 2024, which is 33.96% above the current Free Cash Flow Yield.
-
Peptron, Inc. 52-week low Free Cash Flow Yield is -2.69% on April 17, 2024, which is -286.91% below the current Free Cash Flow Yield.
-
Peptron, Inc. average Free Cash Flow Yield for the last 52 weeks is -1.38%.
Key data
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
Market news
Loading...
KOSDAQ: 087010.KQ
| CEO | Mr. Ho-Il Choi |
| IPO Date | July 22, 2015 |
| Location | South Korea |
| Headquarters | 37-24, Yuseong-daero 1628 beon-gil |
| Employees | 94 |
| Sector | Health Care |
| Industries | |
Description
Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email